CRISPR

First Opinion Robert Brodsky

New sickle cell disease CRISPR treatments can’t make up for the shortage of adult hematologists

The Readout Theresa Gaffney

Morning Rounds: Preterm birth rates vary across the U.S., with the highest in the Southeast

Biotech Jonathan Wosen

STAT Plus: Historic approval of sickle cell gene therapies met with cautious optimism by experts at ASH

Biotech Adam Feuerstein

STAT Plus: A Q&A with the CEO of CRISPR Therapeutics on a historic approval and the road ahead

Biotech Adam Feuerstein

STAT Plus: In historic decision, FDA approves a CRISPR-based medicine for treatment of sickle cell disease

Morning Rounds Elizabeth Cooney

STAT Plus: Morning Rounds: 3D-printed organs, antimicrobial resistance in Ukraine, and other major health stories of the day

The Readout Meghana Keshavan

CRISPR is about to make history. Here’s the 5-minute rundown of what to expect

The Readout LOUD Damian Garde, Allison DeAngelis, and Adam Feuerstein

Listen: CRISPR history, biotech struggles, & a big week for deals

Morning Rounds Elizabeth Cooney

STAT Plus: Morning Rounds: Couples share high blood pressure, and other health stories you should read today

Morning Rounds Theresa Gaffney

STAT Plus: STAT Morning Rounds: Six health news stories you need to start your day

The Readout Meghana Keshavan

STAT Plus: Novartis is building a new radioligand plant in China

Biotech Jason Mast

STAT Plus: How sickle cell became the first disease treated by CRISPR

The Readout Meghana Keshavan

STAT Plus: A new algorithm unveils CRISPR ‘treasure trove’

The Readout Meghana Keshavan

STAT Plus: Merck cough drug doesn’t pass panel scrutiny

The Readout Damian Garde

STAT Plus: The return of biotech’s “bump factor” amid an economic downturn

The Readout LOUD Allison DeAngelis and Adam Feuerstein

Listen: A CRISPR milestone, algorithms amok, & biotech mixology

Biotech Andrew Joseph and Adam Feuerstein

STAT Plus: U.K. approves world’s first CRISPR-based medicine, giving green light to therapy for sickle cell, thalassemia

Biotech Adam Feuerstein

STAT Plus: In first test for base editing, Verve’s one-time treatment lowers cholesterol levels in patients

The Readout Damian Garde

STAT Plus: Your morning biotech news roundup

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: Panel tells FDA that CRISPR sickle cell therapy is safe enough for patients; U.K. is urged to scrap IP demands in trade talks with India

The Readout Damian Garde

STAT Plus: Gene editing has had a big week in the spotlight. Here’s what’s going on

The Readout Damian Garde

STAT Plus: Sarepta’s disappointing data put the FDA in a difficult spot

Biotech Megan Molteni and Adam Feuerstein

STAT Plus: Tracking the FDA advisory panel on the first CRISPR-based treatment for sickle cell disease

Biotech Adam Feuerstein and Megan Molteni

STAT Plus: FDA has some safety concerns about CRISPR-based sickle cell treatment, documents show

Biotech Jason Mast

STAT Plus: In major test for prime editing, scientists successfully correct mutations in monkeys

The Readout Meghana Keshavan

STAT Plus: Johnson & Johnson antiviral pill for dengue shows early efficacy

Biotech Adam Feuerstein

STAT Plus: FDA clears Verve to begin U.S. study of gene-editing treatment for high cholesterol

The Readout Meghana Keshavan

STAT Plus: Why Biogen is purposefully becoming more risk averse, according to Biogen’s CEO

The Readout LOUD Damian Garde, Allison DeAngelis, and Adam Feuerstein

Listen: Live from the 2023 STAT Summit